Bio-Reference Laboratories Inc. (BRLI) Releases Q4 Earnings Guidance
Bio-Reference Laboratories Inc. (NASDAQ:BRLI) updated its fourth quarter earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $0.62-0.64 for the period, compared to the Thomson Reuters consensus estimate of $0.65, Analyst Ratings Network.com reports.
Shares of Bio-Reference Laboratories Inc. (NASDAQ:BRLI) traded up 3.05% during mid-day trading on Wednesday, hitting $33.06. The stock had a trading volume of 97,161 shares. Bio-Reference Laboratories Inc. has a 1-year low of $24.13 and a 1-year high of $37.97. The stock’s 50-day moving average is $31.36 and its 200-day moving average is $28.41. The company has a market cap of $916.3 million and a P/E ratio of 22.91.
Bio-Reference Laboratories (NASDAQ:BRLI) last announced its earnings results on Wednesday, August 27th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.02. The company had revenue of $222.10 million for the quarter, compared to the consensus estimate of $210.44 million. During the same quarter in the previous year, the company posted $0.53 earnings per share. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. Analysts expect that Bio-Reference Laboratories Inc. will post $1.64 EPS for the current fiscal year.
Bio-Reference Laboratories, Inc (NASDAQ:BRLI) is a clinical testing laboratory offering testing, information and related services to physician offices, clinics, hospitals, employers and governmental units.
Receive News & Ratings for Bio-Reference Laboratories Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Reference Laboratories Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.